CPHI (China Pharma Holding) FFO


CPHI China Pharma Holding Inc CPHI
26 GF Score
Price $0.57
GF Value $0.24
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is China Pharma Holding FFO?

FFO (Funds from operations) only applies to REITs.

CPHI
26GF Score
China Pharma Holding Inc CPHI
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is China Pharma Holding (CPHI) Overvalued in 2026?

Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued. The current stock price of $0.57 is trading 137.5% above its estimated GF Value™ of $0.24. GuruFocus considers China Pharma Holding to be Significantly Overvalued.

Key valuation signals for CPHI:

  • FFO:
  • GF Value™: $0.24 vs. price of $0.57 (137.5% above fair value)
  • GF Score™: 26/100 with 3 warning signs

No single metric tells the full story. See the CPHI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Pharma Holding Business Description

Address No. 17, Jinpan Road, Second Floor, Jiahai Building, Hainan Province, Haikou, CHN, 570216
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score

Get the complete analysis for CPHI

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.57
Price
$0.24
GF Value